1 / 9

NDA 21-200

Zelmac ™ (tegaserod). NDA 21-200. Gastrointestinal Advisory Committee Meeting Gaithersburg, Maryland June 26, 2000. Zelmac ™ (tegaserod). Introduction. Mathias Hukkelhoven, PhD Vice President Head, US Drug Regulatory Affairs Novartis Pharmaceuticals Corporation. Proposed Indication.

sileas
Télécharger la présentation

NDA 21-200

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Zelmac™ (tegaserod) NDA 21-200 Gastrointestinal Advisory Committee Meeting Gaithersburg, MarylandJune 26, 2000

  2. Zelmac™ (tegaserod) Introduction Mathias Hukkelhoven, PhD Vice PresidentHead, US Drug Regulatory Affairs Novartis Pharmaceuticals Corporation

  3. Proposed Indication Zelmac™ (tegaserod) is indicated for the treatment of irritable bowel syndrome (IBS) in patients who identify abdominal pain/ discomfort and constipation as their predominant symptoms.

  4. Irritable Bowel Syndrome • Symptoms • Abdominal pain or discomfort • Bloating • Altered bowel function • Frequency of bowel movements • Stool consistency • Chronic or recurrent course • Severity ranging from mild to severe/intractable • Symptoms due to disturbances in GI motility and enhanced visceral sensitivity • Highly prevalent and associated with significant disability and healthcare costs

  5. Spectrum of IBS Patients can have different bowel symptoms over time Diarrhea Alternating Constipation

  6. TegaserodPharmacologic Profile • Potent and selective 5-HT4 receptor partial agonist • Modulates normal and impaired motility throughout the gastrointestinal tract • Modulates intestinal chloride/water secretion • Inhibits visceral sensation upon colorectal distension • Lacks cardiovascular, renal, respiratory, CNS, and endocrine effects

  7. Regulatory Background • No clinical guidelines or medical consensus regarding appropriate outcome measures in IBS • Novartis conferred with medical experts and had several interactions with FDA regarding outcome measures for the 3 tegaserod phase III studies • Specific consultation with GI Division following analysis of first phase III study (B351) and prior to the unblinding and analysis of the remaining 2 phase III studies (B301 and B307)

  8. TegaserodClinical Profile • Totality of data derived from 4,000 subjects of whom 3,000 IBS patients were enrolled in clinical studies, support the following clinical profile • Tegaserod 12 mg/d (6 mg BID) is effective in relieving abdominal pain or discomfort, bloating, and constipation in patients who identify abdominal pain or discomfort and constipation as their predominant symptoms • Tegaserod is safe and well tolerated

  9. Agenda Irritable Bowel Syndrome . . . . . . . . . . Arnold Wald, MD 5-HT4 Receptor Activation . . . . . . Michael Camilleri, MD Efficacy and Safety of Tegaserod . . . . . . . . . . . . . . . . . Martin Lefkowitz, MD Preclinical Findings . . . . . . . . . . . . . Philip Bentley, PhD Review of Data on Ovarian Cysts . . . . . . . . . . . . . . . . . . . . . . Bruce Carr, MD Closing Remarks . . . . . . . . . . . . . . . . Sidney Cohen, MD

More Related